September 23, 2020
A Connecticut federal judge granted Boehringer Ingelheim Pharmaceuticals Inc.'s bid to toss a class action claiming it falsely marketed a lung disease inhaler as containing twice the amount of drug that it actually delivered, saying Wednesday that the consumers' claims lack scientific evidence.